Stock listing
gettex:BA3 Azenta, Inc. Aktie
German listing (gettex) of Azenta, Inc. · home listing NASDAQ:AZTA
Follow Azenta, Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:AZTA
$44.80 USD -3.89 (-8.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AZTA
- Day range
- $44.18 – $46.65 USDNov 20, 2026
- Volume
- 621,104 sharesNov 20, 2026
- Market cap
- $1.96B USDAt the close on Nov 20, 2026 · price × 43.81M shares outstanding
- 52-week range
- $15.93 – $50.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $38.31M USDMedian day 853,748 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:AZTA · Home | $44.80 USD | -3.89 (-8.0%) | 621,104 | $45.97 | $46.65 | $44.18 | $48.69 | Close on Nov 20, 2026 |
| LSE:0HQ1 | $44.73 USD | -4.01 (-8.2%) | 345 | $45.19 | $46.30 | $44.63 | $48.74 | Close on Nov 20, 2026 |
| Frankfurt:BA3 | €41.20 EUR | -3.00 (-6.8%) | — | €42.40 | €42.40 | €41.20 | €44.20 | Close on Nov 20, 2026 |
| Munich:BA3 | €43.20 EUR | -1.60 (-3.6%) | — | €43.20 | €43.20 | €43.20 | €44.80 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AZTA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $44.80 | -3.89 | -8.0% | $45.97 | $46.65 | $44.18 | 621,104 | |
| $48.69 | +2.88 | +6.3% | $46.24 | $48.96 | $45.57 | 695,944 | |
| $45.81 | -1.41 | -3.0% | $47.07 | $48.12 | $45.29 | 1,412,190 | |
| $47.22 | +1.57 | +3.4% | $44.32 | $47.40 | $44.32 | 1,330,950 | |
| $45.65 | +1.79 | +4.1% | $44.26 | $45.68 | $43.15 | 1,114,038 | |
| $43.86 | -5.04 | -10.3% | $46.60 | $47.00 | $43.52 | 910,539 | |
| $48.90 | +8.42 | +20.8% | $46.55 | $50.06 | $43.67 | 2,486,317 | |
| $40.48 | -0.47 | -1.1% | $40.47 | $40.86 | $39.70 | 675,893 | |
| $40.95 | +1.79 | +4.6% | $39.77 | $41.28 | $39.42 | 733,868 | |
| $39.16 | +1.78 | +4.8% | $37.28 | $39.34 | $37.23 | 792,082 | |
| $37.38 | -1.76 | -4.5% | $38.55 | $38.99 | $36.98 | 1,066,153 | |
| $39.14 | +2.00 | +5.4% | $38.51 | $39.61 | $37.66 | 916,363 | |
| $37.14 | +1.59 | +4.5% | $35.66 | $37.44 | $35.05 | 1,033,469 | |
| $35.55 | -3.51 | -9.0% | $39.18 | $39.53 | $35.46 | 957,707 | |
| $39.06 | -2.21 | -5.4% | $39.56 | $40.35 | $38.07 | 895,243 | |
| $41.27 | +0.64 | +1.6% | $40.61 | $41.71 | $40.46 | 825,685 | |
| $40.63 | +1.55 | +4.0% | $39.06 | $41.26 | $39.05 | 900,734 | |
| $39.08 | +1.91 | +5.1% | $37.14 | $40.27 | $36.88 | 1,676,549 | |
| $37.17 | +0.67 | +1.8% | $36.60 | $37.33 | $36.52 | 657,937 | |
| $36.50 | +0.49 | +1.4% | $35.67 | $36.60 | $35.21 | 478,678 | |
| $36.01 | -0.75 | -2.0% | $36.66 | $37.23 | $35.51 | 813,313 | |
| $36.76 | +1.03 | +2.9% | $35.44 | $37.10 | $34.93 | 635,729 | |
| $35.73 | +0.89 | +2.6% | $35.04 | $36.41 | $34.51 | 769,853 | |
| $34.84 | +0.75 | +2.2% | $34.55 | $35.56 | $34.10 | 791,899 | |
| $34.09 | -2.43 | -6.7% | $36.52 | $37.37 | $33.03 | 1,262,519 | |
| $36.52 | -0.66 | -1.8% | $36.95 | $37.11 | $35.20 | 1,217,356 | |
| $37.18 | -0.69 | -1.8% | $37.48 | $38.92 | $37.06 | 1,112,838 | |
| $37.87 | +0.10 | +0.3% | $37.77 | $38.40 | $37.18 | 663,252 | |
| $37.77 | +0.05 | +0.1% | $37.42 | $37.99 | $36.57 | 1,042,169 | |
| $37.72 | +1.72 | +4.8% | $35.94 | $38.34 | $35.88 | 1,163,065 | |
| $36.00 | +0.11 | +0.3% | $35.74 | $36.19 | $34.93 | 1,220,891 | |
| $35.89 | -3.46 | -8.8% | $38.33 | $39.11 | $35.56 | 1,690,988 | |
| $39.35 | -3.38 | -7.9% | $43.76 | $46.41 | $39.33 | 2,544,088 | |
| $42.73 | +3.98 | +10.3% | $39.49 | $43.22 | $38.84 | 2,370,511 | |
| $38.75 | +4.27 | +12.4% | $35.05 | $42.00 | $34.66 | 3,384,485 | |
| $34.48 | -0.41 | -1.2% | $34.92 | $35.03 | $34.19 | 935,976 | |
| $34.89 | +0.61 | +1.8% | $34.37 | $35.24 | $34.14 | 929,060 | |
| $34.28 | +0.03 | +0.1% | $34.21 | $34.45 | $33.66 | 813,906 | |
| $34.25 | +0.23 | +0.7% | $33.58 | $34.71 | $33.28 | 736,977 | |
| $34.02 | -0.18 | -0.5% | $34.36 | $34.39 | $33.67 | 781,096 | |
| $34.20 | +0.11 | +0.3% | $33.69 | $34.82 | $33.51 | 917,803 | |
| $34.09 | -0.19 | -0.6% | $34.15 | $34.88 | $33.88 | 769,257 | |
| $34.28 | +0.53 | +1.6% | $34.00 | $34.86 | $33.72 | 1,131,872 | |
| $33.75 | +0.51 | +1.5% | $33.53 | $33.97 | $33.10 | 718,184 | |
| $33.24 | -0.39 | -1.2% | $33.44 | $33.82 | $33.03 | 1,430,309 | |
| $33.63 | +0.42 | +1.3% | $33.94 | $34.04 | $33.37 | 750,809 | |
| $33.21 | +0.18 | +0.5% | $33.03 | $33.93 | $32.98 | 729,672 | |
| $33.03 | +0.99 | +3.1% | $31.93 | $33.82 | $31.93 | 718,488 | |
| $32.04 | +1.19 | +3.9% | $30.88 | $32.28 | $30.27 | 688,779 | |
| $30.85 | +0.67 | +2.2% | $30.56 | $31.08 | $30.18 | 748,607 | |
| $30.18 | +0.03 | +0.1% | $29.74 | $30.38 | $29.64 | 853,748 | |
| $30.15 | -0.67 | -2.2% | $30.57 | $30.72 | $30.06 | 879,590 | |
| $30.82 | -0.51 | -1.6% | $30.82 | $31.66 | $30.66 | 1,159,911 | |
| $31.33 | +0.15 | +0.5% | $30.66 | $31.58 | $30.61 | 751,929 | |
| $31.18 | -0.55 | -1.7% | $32.26 | $32.44 | $30.81 | 758,635 | |
| $31.73 | +0.16 | +0.5% | $31.60 | $32.19 | $31.18 | 792,770 | |
| $31.57 | -1.08 | -3.3% | $32.56 | $33.41 | $30.57 | 1,453,941 | |
| $32.65 | -0.30 | -0.9% | $32.73 | $33.02 | $32.27 | 475,580 | |
| $32.95 | -0.66 | -2.0% | $33.61 | $33.76 | $32.49 | 659,508 | |
| $33.61 | +0.04 | +0.1% | $33.57 | $33.94 | $33.29 | 490,986 | |
| $33.57 | +0.36 | +1.1% | $32.83 | $33.65 | $32.45 | 602,532 | |
| $33.21 | +0.33 | +1.0% | $33.06 | $33.93 | $32.77 | 988,849 | |
| $32.88 | -4.52 | -12.1% | $33.32 | $34.31 | $31.86 | 1,895,730 | |
| $37.40 | +0.89 | +2.4% | $36.55 | $37.49 | $36.05 | 647,100 | |
| $36.51 | +0.89 | +2.5% | $35.25 | $37.15 | $35.14 | 706,922 |
- Ticker
- gettex:BA3
- Asset type
- Stock
- Sector
- Health care
- Industry
- Diagnostics & research services
- Exchange
- gettex
- Currency
- EUR
What changed lately
Latest news release · Nov 17, 2026
Azenta to Participate in the 9th Annual Evercore Healthcare Conference
Latest earnings call · Nov 11, 2026
Azenta (NASDAQ:AZTA) Q4 2026 Earnings Call
Replay and transcript
Latest deck · Nov 11, 2026
Q4 2026 Earnings Presentation
Earnings · 14 slides
Latest news
Azenta to Participate in the 9th Annual Evercore Healthcare Conference
Nov 17, 2026
Closed $48.69 (+6.3%) on Nov 18, 2026
Azenta Reports Fourth Quarter and Full Year Results for Fiscal 2026, Ended September 30, 2026.
Nov 10, 2026
Closed $48.90 (+20.8%) on Nov 11, 2026
Azenta Announces Strategic Investments to Advance the Next Generation of GENEWIZ Gene Synthesis Capabilities
Oct 30, 2026
Closed $39.06 (-5.4%) on Oct 30, 2026
Azenta Announces Fiscal 2026 Fourth Quarter and Full Year Conference Call and Webcast
Oct 28, 2026
Closed $41.27 (+1.6%) on Oct 29, 2026
Azenta Receives Full Repayment of $35 Million Vendor Loan Related to Sale of B Medical Systems
Sep 4, 2026
Closed $31.33 (+0.5%) on Sep 4, 2026
Azenta announces leadership transition
Aug 24, 2026
Closed $32.88 (-12.1%) on Aug 24, 2026
Azenta Reports Third Quarter Results for Fiscal 2026, Ended June 30, 2026.
Aug 4, 2026
Closed $31.82 (+5.6%) on Aug 5, 2026
Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast
Jul 22, 2026
Closed $28.30 (+4.2%) on Jul 23, 2026
Azenta Completes Sale of B Medical Systems
Jul 8, 2026
Closed $24.51 (-3.4%) on Jul 8, 2026
Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report
May 21, 2026
Closed $20.18 (+3.3%) on May 22, 2026
Azenta, Inc. on 6ix
- Sector
- Health care
- Industry
- Diagnostics & research services
- News releases
- 21 in the last 12 months · 192 in all · newest Nov 17, 2026 · oldest 2019
- Calls
- 20 calls with a replay · 20 with a transcript · latest Nov 11, 2026
- Decks
- 52 decks · latest Nov 11, 2026
Where Azenta, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:AZTA · Home listing | NASDAQ | United States | USD |
| LS Exchange:257275 | LS Exchange | Germany | EUR |
| Tradegate:BA3 | Tradegate | Germany | EUR |
| gettex:BA3 · This page | gettex | Germany | EUR |
| LSE:0HQ1 | LSE | United Kingdom | USD |
| Lang & Schwarz:257275 | Lang & Schwarz | Germany | EUR |
| BOATS:AZTA | BOATS | United States | USD |
| B3:A2ZT34 | B3 | Brazil | BRL |
| Dusseldorf:BA3 | Dusseldorf | Germany | EUR |
| Frankfurt:BA3 | Frankfurt | Germany | EUR |
| Munich:BA3 | Munich | Germany | EUR |
| Stuttgart:BA3 | Stuttgart | Germany | EUR |
| BX Swiss:BA3 | BX Swiss | Switzerland | CHF |
Valuation
EV/sales 2.6× against a median of 6.7×: 3rd lowest of 11 Diagnostics & research services companies shown. Statements: Year to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.63B USD
- P/E
- Loss
- EV/sales
- 2.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 1.4×
- Gross margin
- 44.2%
- Operating margin
- −28.1%
- Net margin
- −26.9%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.59
Diagnostics & research services: the 10 companies nearest in size, of 302 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Azenta, Inc. · NASDAQ:AZTA | US$1.96B | US$1.63B | n/a | 2.6× | n/a | 1.4× | −26.9% | 0.0× | 1.59 |
| Veracyte, Inc. · NASDAQ:VCYT | US$2.03B | US$1.70B | 16.0× | 2.9× | 14.0× | 1.4× | 21.8% | 0.0× | 1.34 |
| OneSource Specialty Pharma Limited · NSE:ONESOURCE | US$1.99B | US$2.18B | n/a | 12.0× | 50.9× | 3.1× | −0.1% | 0.3× | n/a |
| Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A · SSE:603456 | US$1.97B | US$1.77B | 22.0× | 2.2× | n/a | 1.5× | 11.3% | 0.0× | n/a |
| Syngene International Ltd. · NSE:SYNGENE | US$1.96B | US$1.96B | 97.5× | 5.2× | 20.0× | 3.7× | 5.3% | 0.1× | n/a |
| Cohance Lifesciences Ltd · NSE:COHANCE | US$1.91B | US$1.88B | 167× | 8.1× | 55.1× | 4.5× | 5.0% | 0.1× | n/a |
| Alamar Biosciences, Inc. · NASDAQ:ALMR | US$1.84B | US$1.66B | n/a | 14.5× | n/a | 6.1× | −48.2% | 0.1× | 1.70 |
| Fortrea Holdings Inc. · NASDAQ:FTRE | US$1.79B | US$2.62B | n/a | 1.0× | 28.7× | 3.4× | −2.6% | 2.0× | 1.68 |
| ChemoMetec A/S · OMXCOP:CHEMM | US$1.72B | US$1.68B | 58.0× | 22.3× | 40.6× | 16.1× | 39.5% | 0.0× | n/a |
| GemPharmatech Co., Ltd. Class A · SSE:688046 | US$1.65B | US$1.49B | 54.4× | 10.5× | n/a | 4.7× | 21.5% | 0.0× | n/a |
| PolyPeptide Group AG · SIX:PPGN | US$1.62B | US$1.71B | n/a | 4.0× | 34.2× | 4.2× | −5.4% | 0.4× | n/a |
| Median of the others | US$1.87B | US$1.74B | 56.2× | 6.7× | 34.2× | 4.0× | 5.1% | 0.1× | 1.68 |
Forecasts
2 strong buy · 1 buy · 3 hold · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 39.40 USD · Analysts' mean
- EPS, year to Sep 2027
- 0.48 · 4 analysts
- Revenue, year to Sep 2027
- 641.9M · 5 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Martin Madaus | interim President and CEO |
| Erica J. McLaughlin | Executive Vice President, CFO and Head of Corporate Strategy |
| Trey Martin | President of its Multiomics business |
| Maria Isabel CuartasManager | Investor Relations |
Board
| Director | Role |
|---|---|
| Frank E. Casal | Board Chair |
| Erica J. McLaughlin | Executive Vice President, CFO and Head of Corporate Strategy |
| Martin Madaus | interim President and CEO |
| Quentin G. Koffey | Director |
| Robyn C. Davis | Director |
| Tina S. Nova | Director |
| William L. Cornog | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Azenta (NASDAQ:AZTA) Q4 2026 Earnings Call | Wed, Nov 11, 2026 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q3 2026 Earnings Call | Wed, Aug 05, 2026 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q2 2026 Earnings Call | Wed, May 06, 2026 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q1 2026 Earnings Call | Wed, Feb 04, 2026 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q4 2025 Earnings Call | Fri, Nov 21, 2025 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q3 2025 Earnings Call | Tue, Aug 05, 2025 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q2 2025 Earnings Call | Wed, May 07, 2025 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q1 2025 Earnings Call | Wed, Feb 05, 2025 · 8:30 AM ET | Replay |
| Azenta (NASDAQ:AZTA) Q4 2024 Earnings Call | Tue, Nov 12, 2024 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q3 2024 Earnings Call | Tue, Aug 06, 2024 · 4:30 PM ET | Replay |
All 20 calls
| Call | When | Status |
|---|---|---|
| Azenta (NASDAQ:AZTA) Q2 2024 Earnings Call | Wed, May 08, 2024 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q1 2024 Earnings Call | Wed, Feb 07, 2024 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q4 2023 Earnings Call | Mon, Nov 13, 2023 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q3 2023 Earnings Call | Tue, Aug 08, 2023 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q2 2023 Earnings Call | Tue, May 09, 2023 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q1 2023 Earnings Call | Wed, Feb 08, 2023 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q4 2022 Earnings Call | Mon, Nov 14, 2022 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q3 2022 Earnings Call | Tue, Aug 09, 2022 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q2 2022 Earnings Call | Mon, May 09, 2022 · 4:30 PM ET | Replay |
| Azenta (NASDAQ:AZTA) Q1 2022 Earnings Call | Tue, Feb 08, 2022 · 4:30 PM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q4 2026 | Nov 10, 2026 · After close | +20.8% |
| Q3 2026 | Aug 4, 2026 · After close | +5.6% |
| Q2 2026 | May 5, 2026 · After close | −25.3% |
| Q1 2026 | Feb 4, 2026 · Before open | −22.8% |
| Q4 2025 | Nov 11, 2025 · Before open | +1.3% |
| Q3 2025 | Aug 5, 2025 · Before open | −17.0% |
| Q2 2025 | May 7, 2025 · Before open | −0.6% |
| Q1 2025 | Feb 5, 2025 · Before open | +3.4% |
| Q4 2024 | Nov 12, 2024 · After close | −3.2% |
| Q3 2024 | Aug 6, 2024 · After close | −8.9% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q2 2024 | May 8, 2024 · After close | −2.9% |
| Q1 2024 | Feb 7, 2024 · After close | −1.6% |
| Q4 2023 | Nov 13, 2023 · After close | +13.9% |
| Q3 2023 | Aug 8, 2023 · After close | +20.3% |
| Q2 2023 | May 9, 2023 · After close | −18.9% |
| Q1 2023 | Feb 8, 2023 · After close | −18.3% |
| Q4 2022 | Nov 14, 2022 · After close | +21.8% |
| Q3 2022 | Aug 9, 2022 · After close | −3.0% |
| Q2 2022 | May 9, 2022 · After close | +5.6% |
| Q1 2022 | Feb 8, 2022 · After close | +3.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q4 2026 Earnings Presentation | Earnings | 14 slides | Nov 11, 2026 |
| Q4 2026 Earnings Presentation | Earnings | 14 slides | Nov 11, 2026 |
| Q3 2026 Earnings Presentation | Earnings | 13 slides | Aug 5, 2026 |
| Q2 2026 Earnings Presentation | Earnings | 13 slides | May 6, 2026 |
| Q1 2026 Earnings Presentation | Earnings | 13 slides | Feb 4, 2026 |
| Investor Day (December 2025) | Investor day | 67 slides | Dec 10, 2025 |
| Investor Day (December 2025) | Investor day | 62 slides | Dec 10, 2025 |
| Q4 2025 Earnings Presentation | Earnings | 14 slides | Nov 21, 2025 |
| Q3 2025 Earnings Presentation | Earnings | 13 slides | Aug 5, 2025 |
| Q2 2025 Earnings Presentation | Earnings | 13 slides | May 7, 2025 |
Show 50 decks
This page holds 50 of 52 decks. Open Decks
Financials
Annual, in USD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 621.7M | 593.8M | 573.4M | 551.5M | 555.5M | 513.7M | 388.5M | 334.2M | 631.6M | 527.5M |
| Cost of revenue | 346.7M | 323.5M | 318.8M | 312.3M | 299.9M | 269.9M | 216.4M | 199.6M | 385.5M | 425.5M |
| Gross profit | 275.0M | 270.3M | 254.6M | 239.2M | 255.6M | 243.8M | 172.1M | 134.6M | 246.1M | 198.9M |
| Research and development | 37.9M | 30.4M | 31.5M | 32.1M | 27.5M | 22.4M | 17.8M | 17.3M | 46.9M | 39.9M |
| Selling, general and administrative | 257.5M | 261.6M | 263.0M | 263.7M | 251.5M | 252.1M | 190.3M | 163.3M | 167.0M | 141.5M |
| Operating income | -174.7M | -26.8M | -51.3M | -61.2M | -24.7M | -31.1M | -36.6M | -47.4M | 31.4M | 14.3M |
| Depreciation and amortization | 56.5M | 61.2M | 90.7M | 85.6M | 53.7M | 65.3M | 65.5M | 54.5M | 37.4M | 28.1M |
| EBITDA | -118.2M | 34.4M | 39.5M | 24.3M | 29.0M | 34.2M | 28.9M | 7.02M | 68.8M | 42.5M |
| Interest expense | 478.0K | 4.59M | 2.04M | 2.94M | 22.3M | 9.52M | 408.0K | |||
| Income before tax | -151.0M | -7.14M | -19.1M | -20.0M | -9.94M | -49.0M | -40.3M | -84.0M | 20.5M | 14.5M |
| Income tax | 6.86M | -31.6M | 5.24M | -12.0M | 1.35M | -20.1M | -13.9M | -22.8M | -47.3M | 3.38M |
| Net income | -167.0M | -55.8M | -164.9M | -14.6M | 2.13B | 110.7M | 64.9M | 437.4M | 116.6M | 62.6M |
| Earnings per share, basic | -3.70 | -1.22 | -3.10 | -0.22 | 28.48 | 1.49 | 0.88 | 6.08 | 1.65 | 0.90 |
| Earnings per share, diluted | -3.70 | -1.22 | -3.10 | -0.22 | 28.48 | 1.49 | 0.88 | 6.04 | 1.64 | 0.89 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 193.8M | 279.8M | 280.0M | 649.5M | 658.3M | 227.4M | 250.6M | 256.6M | 197.7M | 101.6M |
| Short-term investments | 138.9M | 61.1M | 151.2M | 338.9M | 911.8M | 81.0K | 51.0K | 34.1M | 46.3M | 28.0K |
| Receivables | 143.4M | 142.2M | 154.2M | 156.5M | 163.8M | 119.9M | 94.8M | 165.6M | 125.2M | 93.5M |
| Inventory | 77.1M | 75.0M | 71.3M | 128.2M | 85.5M | 60.4M | 37.1M | 99.4M | 97.0M | 73.4M |
| Current assets | 623.5M | 708.3M | 833.0M | 1.42B | 2.46B | 777.4M | 649.5M | 647.1M | 564.1M | 351.8M |
| Property, plant and equipment | 272.3M | 154.5M | 180.4M | 112.1M | 100.7M | 60.0M | 57.0M | |||
| Goodwill | 546.3M | 702.4M | 691.4M | 675.4M | 513.6M | 469.4M | 453.2M | 440.8M | 255.9M | 207.2M |
| Total assets | 1.71B | 2.06B | 2.10B | 2.89B | 3.72B | 1.82B | 1.56B | 1.52B | 1.10B | 766.6M |
| Accounts payable | 55.2M | 37.7M | 33.3M | 35.8M | 38.7M | 42.4M | 25.7M | 58.9M | 44.7M | 49.1M |
| Current liabilities | 233.1M | 237.7M | 206.1M | 210.9M | 230.5M | 345.1M | 211.1M | 272.3M | 164.6M | 146.8M |
| Long-term debt | 49.7M | 49.6M | 50.3M | 194.1M | ||||||
| Total debt | 111.2M | 70.7M | 60.4M | 49.2M | 49.7M | 50.4M | 51.1M | 196.1M | ||
| Total liabilities | 311.2M | 332.6M | 332.4M | 351.2M | 352.7M | 494.2M | 345.7M | 377.0M | 377.4M | 159.0M |
| Shareholders' equity | 1.40B | 1.73B | 1.77B | 2.53B | 3.36B | 1.33B | 1.21B | 1.14B | 717.8M | 607.6M |
| Shares outstanding | 41.8M | 45.9M | 45.6M | 57.8M | 75.0M | 74.3M | 73.8M | 72.3M | 70.7M | 69.8M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 57.5M | 72.2M | 49.7M | 5.83M | -466.0M | 149.9M | 37.9M | 90.9M | 74.0M | 96.2M |
| Capital spending | -30.1M | -33.9M | -37.4M | -39.4M | -73.4M | -52.8M | -39.9M | -23.9M | -12.8M | -12.7M |
| Free cash flow | 27.4M | 38.3M | 12.4M | -33.6M | -539.5M | 97.1M | -2.06M | 67.0M | 61.2M | 83.5M |
| Cash from investing | -33.8M | -90.5M | 224.7M | 431.4M | 1.47B | -146.3M | -22.7M | 211.3M | -148.5M | -54.2M |
| Cash from financing | -119.5M | -9.59M | -659.2M | -840.5M | -62.8M | -25.9M | -27.0M | -191.2M | 170.3M | -25.9M |
| Dividends paid | 0 | 0 | -7.49M | -29.7M | -29.5M | -28.9M | -28.3M | -27.9M | ||
| Share buybacks | -118.3M | 0 | -661.7M | -838.5M | 0 | 828.0K | 828.0K | 686.4M | 197.6M | |
| Change in cash | -98.4M | -24.3M | -363.1M | -357.3M | 756.0M | -17.2M | -2.65M | 107.5M | 96.1M | 16.5M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-K · Annual report | Nov 19, 2026 | Annual report | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 8-K · Current report | Oct 30, 2026 | Material contract | SEC |
| 4 · Change in ownership | Oct 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Oct 7, 2026 | Current report | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Sep 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 17, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2026 | Current report | SEC |
| 8-K · Current report | Aug 24, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Aug 11, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 10, 2026 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 6, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 4, 2026 | Insider trade | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 8-K · Current report | Jul 8, 2026 | Acquisition or disposal | SEC |
| SD · Specialized disclosure | May 26, 2026 | ESG report | SEC |
| 4 · Change in ownership | May 19, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 8, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 8, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 28, 2026 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Apr 16, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 7, 2026 | Management or board change | SEC |
| 8-K · Current report | Apr 2, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 4, 2026 | Material contract | SEC |
| 4/A · Change in ownership, amended | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Feb 4, 2026 | Results | SEC |
| 8-K · Current report | Jan 30, 2026 | Management or board change | SEC |
| 8-K · Current report | Jan 29, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Dec 29, 2025 | Material contract | SEC |
| DEFR14A | Dec 19, 2025 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Dec 19, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Dec 18, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 18, 2025 | Meeting notice | SEC |
| 8-K · Current report | Dec 10, 2025 | Current report | SEC |
| 10-K · Annual report | Dec 4, 2025 | Annual report | SEC |
| 4/A · Change in ownership, amended | Dec 3, 2025 | Insider trade | SEC |
| NT 10-K · Late filing notice | Dec 2, 2025 | Explanation request | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 25, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 25, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 25, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 25, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 21, 2025 | Results | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 14, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 14, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 14, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 14, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Nov 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 18, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Jul 2, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Jun 4, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Jun 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 3, 2025 | Insider trade | SEC |
| SD · Specialized disclosure | May 30, 2025 | ESG report | SEC |
| 4 · Change in ownership | May 27, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 27, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2025 | Insider trade | SEC |
| 8-K · Current report | May 16, 2025 | Management or board change | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 12, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | May 9, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 29, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Apr 9, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Feb 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Feb 10, 2025 | Quarterly report | SEC |
| 8-K · Current report | Feb 5, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 4, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 4, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 30, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Dec 17, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Dec 17, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Dec 17, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Dec 9, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Dec 6, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 5, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 2, 2024 | Insider trade | SEC |
| 10-K · Annual report | Nov 26, 2024 | Annual report | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 14, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 12, 2024 | Results | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 8, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Nov 4, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 4, 2024 | Material contract | SEC |
| SC 13G · Big-stake notice | Oct 31, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Oct 21, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 11, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2024 | Insider trade | SEC |
| 8-K · Current report | Sep 4, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Aug 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 1, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 29, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 25, 2024 | Other filings | SEC |
| SD · Specialized disclosure | May 30, 2024 | ESG report | SEC |
| 4 · Change in ownership | May 22, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 20, 2024 | Other filings | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Management or board change | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| 4 · Change in ownership | Apr 2, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2024 | Other filings | SEC |
| 8-K · Current report | Mar 14, 2024 | Current report | SEC |
| 4 · Change in ownership | Mar 11, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 8, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Mar 7, 2024 | Other filings | SEC |
| 144 · Notice of proposed sale | Feb 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 13, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Feb 8, 2024 | Quarterly report | SEC |
| 144 · Notice of proposed sale | Feb 8, 2024 | Other filings | SEC |
| 8-K · Current report | Feb 7, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Feb 2, 2024 | Insider trade | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Azenta, Inc.’s releases
- Common shares
- 43,808,393
- Fully diluted
- 43,808,393
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 43,808,393 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 43,808,393 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Tina Susan Nova Other companies: Aurinia Pharmaceuticals Inc (Director · Since at least May 15, 2025); Exagen Inc. (Director · Since at least Sep 18, 2019); CapForce Inc. (Director · Apr 24, 2017 – Sep 2, 2019 · Past); Veracyte, Inc. (President, CLIA U.S. · Nov 12, 2015 – Mar 3, 2022 · Past); NanoString Technologies Inc (Director · Apr 29, 2014 – Apr 29, 2014 · Past); DMK Pharmaceuticals Corporation (Director · Feb 10, 2011 – Oct 16, 2013 · Past); Genoptix Inc (President and CEO, Director · Oct 29, 2007 – Mar 7, 2011 · Past); Cypress Bioscience Inc (Director · Apr 26, 2007 – Jan 4, 2010 · Past); Arena Pharmaceuticals Inc (Director · Jul 28, 2006 – Mar 11, 2022 · Past) | Director · Since at least Feb 3, 2023 |
| Ellen M. Zane Other companies: GMR Solutions Inc. (Director · Since at least Jul 1, 2026); Synchrony Financial (Director · Since at least Feb 1, 2019); Boston Scientific Corporation (Board of Directors · Since at least Apr 15, 2016); Haemonetics Corporation (Chair · Since at least Jul 27, 2012); Press Ganey Holdings Inc (Director · May 20, 2015 – Oct 21, 2016 · Past); Lincare Holdings Inc (Director · Nov 1, 2010 – Aug 13, 2012 · Past); PAREXEL International Corp (Director · Jul 20, 2006 – Sep 29, 2017 · Past) | Director · May 9, 2012 – Aug 8, 2023 · Past |
| Didier Hirsch Other companies: Sophia Genetics SA (Board Member · Since at least Mar 18, 2026); Knowles Corporation (Director · Dec 18, 2014 – Apr 29, 2025 · Past); Logitech International S.A. (Director · Sep 5, 2012 – Sep 8, 2021 · Past); International Rectifier Corp (Director · Mar 26, 2012 – Jan 13, 2015 · Past); Agilent Technologies, Inc. (Sr. VP and CFO · Nov 16, 2011 – Dec 7, 2017 · Past) | Director · Jan 30, 2024 – Nov 18, 2024 · Past |
| Amin J Khoury Other companies: Molekule Group Inc. (Director · Nov 23, 2021 – Apr 18, 2023 · Past); KLX Energy Services Holdings, Inc. (Director · Aug 24, 2018 – Jun 11, 2020 · Past); KLX Inc (Chairman & Chief Exec. Officer, Director · Nov 26, 2014 – Oct 9, 2018 · Past); B/E Aerospace Inc (Executive Chairman, Director · Mar 24, 2006 – Apr 13, 2017 · Past) | Director · Oct 26, 2005 – Apr 12, 2006 · Past |
| A Clinton Allen Other companies: Steinway Musical Instruments Inc (Director · Mar 30, 2007 – Sep 4, 2009 · Past); Collectors Universe Inc (Director · Dec 29, 2006 – Dec 4, 2018 · Past); LKQ Corporation (Director · Oct 2, 2006 – Mar 16, 2020 · Past) | Director · Mar 23, 2006 – Sep 25, 2020 · Past |
| Dorothy Puhy Other companies: MiMedx Group, Inc (Director · Since at least Mar 1, 2024); ABIOMED Inc (Director · Jul 1, 2009 – Dec 22, 2022 · Past); Eaton Vance Corp (Director · Oct 31, 2008 – Feb 12, 2021 · Past) | Director · Feb 13, 2023 – Feb 13, 2023 · Past |
| Michael Rosenblatt Other companies: Axcella Health Inc (Director · May 19, 2022 – May 19, 2022 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Merck & Company, Inc. (Exec V-P & Chief Med Officer · Dec 16, 2009 – May 10, 2016 · Past) | Director · Sep 4, 2018 – Feb 12, 2024 · Past |
| William L. Cornog Other companies: LiveWire Group, Inc. (Director · Since at least Sep 26, 2022); BrightView Holdings, Inc. (Director · Since at least May 9, 2022); Laureate Education, Inc. (Director · May 26, 2021 – May 25, 2022 · Past) | Director · Since at least Nov 4, 2024 |
| Herman V. Cueto Other companies: BETA Technologies, Inc. (Chief Financial Officer · Since at least Nov 3, 2025); Dentsply Sirona Inc. (Interim Chief Financial Officer · Dec 2, 2024 – Nov 4, 2026 · Past) | EVP, Chief Financial Officer · Oct 16, 2023 – Nov 19, 2024 · Past |
| Kirk P Pond Other companies: Sensata Technologies Holding plc (Director · Mar 9, 2011 – Jun 5, 2018 · Past); WEX Inc. (Director · May 15, 2009 – May 11, 2018 · Past) | Director · Feb 11, 2009 – Dec 20, 2019 · Past |
All 48 people
| Person | Seat |
|---|---|
| Krishna Palepu Other companies: Allegro MicroSystems, Inc. (Baker Foundation Professor of Business Administration, and Senior Associate Dean, Business in Global Society, at the Harvard Business School · Since at least Jan 31, 2025); Polymedica Corp (Director · Jun 29, 2006 – Oct 31, 2007 · Past) | Director · Mar 23, 2006 – Feb 13, 2023 · Past |
| Mark S Wrighton Other companies: Corning Incorporated (Director · Feb 2, 2011 – Feb 12, 2025 · Past); Cabot Corporation (Director · Jan 14, 2011 – Jan 7, 2021 · Past) | Director · Feb 10, 2011 – Feb 11, 2022 · Past |
| Martin Madaus Other companies: Haemonetics Corporation (Director · Since at least Jul 24, 2026); Repligen Corporation (Chair of the Board · Since at least Jan 6, 2026) | interim President and CEO · Since Aug 24, 2026 |
| Stephen S. Schwartz Other companies: Onto Innovation Inc. (Director · Since at least Jul 16, 2024); Spire Inc. (Director · Feb 1, 2021 – Feb 3, 2023 · Past) | CEO, Director · Nov 13, 2020 – Nov 15, 2023 · Past |
| Tina Nova Other companies: Aurinia Pharmaceuticals Inc (Board Director · Since at least Nov 4, 2026); Exagen Inc. (Executive Chair · Since at least Nov 4, 2026) | Director · Since at least Nov 4, 2026 |
| Alan J Malus Other companies: Thermo Fisher Scientific Inc (Executive Vice President · Aug 25, 2015 – Mar 10, 2016 · Past) | Director · Since at least Nov 6, 2024 |
| Clinton M Haris Other companies: Entegris, Inc. (SVP & President, APS Division · Since at least Jun 13, 2016) | SVP, Brooks Life Sciences · May 5, 2010 – Nov 8, 2013 · Past |
| Dipal Doshi Other companies: Entrada Therapeutics, Inc. (Chief Executive Officer · Since at least Jun 27, 2022) | Director · Since at least Jan 30, 2025 |
| Erica J. McLaughlin Other companies: Cabot Corporation (President and Chief Executive Officer · Since at least May 15, 2018) | Executive Vice President, CFO and Head of Corporate Strategy · Since at least Apr 3, 2020 |
| John Marotta Other companies: Senseonics Holdings, Inc. (Director · Oct 31, 2022 – Nov 2, 2022 · Past) | President and CEO, Director · Since at least Sep 9, 2024 |
| Quentin G. Koffey Other companies: Masimo Corporation (Vice Chairman · Since at least Jan 21, 2025) | Director · Since at least Nov 1, 2024 |
| Vandana Sriram Other companies: Quanterix Corporation (Chief Financial Officer · Since at least Aug 21, 2023) | SVP Finance & Corp. Controller · Feb 1, 2022 – Jan 31, 2023 · Past |
| Violetta Hughes Other companies: Repligen Corporation (Chief Accounting Officer · Since at least Sep 1, 2025) | VP, Chief Accounting Officer · Aug 31, 2023 – Feb 3, 2025 · Past |
| William E Martin III Other companies: Maravai LifeSciences Holdings, Inc. (Chief Executive Officer · Sep 30, 2022 – Mar 17, 2025 · Past) | President Multiomics · Since at least Apr 6, 2026 |
| Alfred Woollacott III | Director · Mar 23, 2006 – Dec 23, 2021 · Past |
| David Dong Wang | SVP & GM, SMS · Nov 10, 2023 – Dec 4, 2024 · Past |
| Ephraim Starr | SVP, Gen Counsel & Secretary · Since at least May 15, 2025 |
| Erik J Bello | VP Chief Accounting Officer · Since at least Aug 31, 2026 |
| Frank Casal | Director · Since at least Nov 5, 2021 |
| Frank E. Casal | Board Chair · Since at least Aug 24, 2026 |
| Ginger Zhou | SVP and GM, Multiomics · Since at least Nov 15, 2022 |
| Jason Joseph | SVP, General Counsel, Secy. · Nov 13, 2020 – Nov 19, 2024 · Past |
| John Lillig | SVP, MD, Brooks Life Sciences · Aug 2, 2011 – Jul 31, 2012 · Past |
| Kimberly Crowley | SVP, Chief HR Officer · Aug 3, 2021 – Jan 31, 2023 · Past |
| Kush Mirchandani | SVP, Worldwide Sales · Feb 7, 2012 – Dec 4, 2013 · Past |
| Lawrence Y Lin | EVP, CFO and Treasurer · Since at least Nov 28, 2024 |
| Linda De Jesus | Chief Commercial Officer, LS · Aug 3, 2021 – Jul 29, 2022 · Past |
| Lindon G Robertson | EVP & Chief Financial Officer · Nov 6, 2017 – Nov 15, 2023 · Past |
| Maria Isabel CuartasManager | Investor Relations · Since at least Apr 7, 2026 |
| Marvin G Schorr | Director · Feb 11, 2009 – Feb 10, 2011 · Past |
| Mitchell Coyne | SVP and GM, Life Sciences Proj · Nov 17, 2022 – Nov 17, 2022 · Past |
| Olga Pirogova | SVP and CHRO · Since at least Nov 10, 2023 |
| Ralf K Wuellner | President, Global Cust Op Grp · Feb 8, 2008 – Jun 8, 2009 · Past |
| Robin Vacha | SVP, GM Life Science Products · Nov 5, 2020 – Feb 1, 2024 · Past |
| Robyn C. Davis | Director · Since at least Jun 28, 2019 |
| Timothy S Mathews | Principal Accounting Officer · May 19, 2008 – May 23, 2013 · Past |
| Trey Martin | President of its Multiomics business · Since at least Apr 7, 2026 |
| William T Montone | SVP, Human Resources · Feb 7, 2012 – Sep 27, 2021 · Past |
Log in to ask 6ix AI your own questions about Azenta, Inc.